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(ANOVA) were used to investigate relations between EQ-5D
scores and categories of BMI (underweight (<18.5), normal
(18.5–<25), overweight (25–<30), obese (30–<40) and extremely
obese (>40). RESULTS: The overall HRQOL was signiﬁcantly
lower for people with T2D compared to non-diabetic patients,
with EQ-5D scores of 0.795 versus 0.867, respectively (p < 0.01).
An ANOVA showed that the non-diabetic obese subgroup (BMI
>−30) had a signiﬁcant reduced HRQOL compared to others 
(p < 0.05). The HRQOL for people with T2D was signiﬁcantly
(p < 0.05) lower for the morbidly obese (BMI >40) compared to
people in the normal weight band (BMI of 18.5–<25). The
HRQOL was lower for people with T2D across all BMI cate-
gories compared to non-diabetics. CONCLUSION: These ﬁnd-
ings suggest that obesity in the general adult population in
England has a signiﬁcant impact on HRQOL. The impact of
obesity on HRQOL is particularly evident in people with T2D
who are further burdened by the impact of their disease.
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OBJECTIVES: To (1) determine the prevalence of depression in
primary care patients with type 2 diabetes mellitus (T2DM) and
(2) compare HRQoL in diabetic patients based on the severity
of depressive symptoms. METHODS: Primary care patients with
T2DM were recruited during their scheduled clinic appoint-
ments. Self-reported data on demographic characteristics were
collected via a survey. Data on Hemoglobin A1C values and
comorbid conditions were collected from patient charts. The
Zung self-rating depression scale was used to measure depressive
symptoms and the SF-8 was used to measure HRQoL. Analysis
of variance (ANOVA) was used to compare HRQoL summary
scores and domain scores for general health (GH), physical func-
tioning (PF), role physical (RP), bodily pain (BP), vitality (VI),
social functioning (SF), mental health (MH) and role emotional
(RE) in diabetic patients based on the severity of symptoms.
RESULTS: A total of 217 surveys were collected with a usable
response rate of 93%. The mean age of the overall sample was
57.3 years (SD = 11.9), 62.2% were female and 61% were His-
panic. The Zung self-rating depression scale indicated that
72.1% of patients met criteria for depression. Scores for the
domains of GH, PF, RP, BP, VI, SF, MH and RE decreased sig-
niﬁcantly (p < 0.001) as the severity of depressive symptoms
increased. Similarly, ANOVA results showed that summary
scores for PCS-8 (F = 24.16, p < 0.001) and MCS-8 (F = 40.00,
p < 0.001) decreased signiﬁcantly as depressive symptom sever-
ity increased. Post-hoc analyses revealed signiﬁcant differences
between groups. CONCLUSION: Patients with T2DM were
found to have a high prevalence of depressive symptoms, includ-
ing symptoms of severe depression. Mental as well as physical
HRQoL decreased signiﬁcantly as the severity of depressive
symptoms increased. Detection and treatment of depression 
may help to improve HRQoL in patients with type 2 diabetes
mellitus.
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OBJECTIVES: Understanding the impact of diabetes on quality
of life may provide impetus for education and prevention. This
study assessed differences in health-related quality of life
(HRQoL) across respondents with type 2 diabetes (T2D) and
groups with varying levels of cardiometabolic risk for develop-
ing T2D. METHODS: The Study to Help Improve Early evalu-
ation and management of risk factors leading to Diabetes
(SHIELD) is a US longitudinal study of individuals with or at
risk for T2D. Respondents without diabetes but with 3–5 car-
diometabolic risk factors for T2D (abdominal obesity, BMI ≥28
kg/m2, reported diagnosis of cholesterol problems, hypertension
or coronary heart disease or stroke) were classiﬁed as high risk
and respondents with ≤2 of these risk factors as low risk.
HRQoL was measured by the EQ-5D visual analog scale (VAS)
and index utility score. Baseline mean VAS and utility scores
(using US population values) were compared across the three
respondent groups using analysis of variance with post-hoc
testing. RESULTS: Mean VAS scores for T2D and high-risk
respondents (66.8 and 70.4, respectively) were signiﬁcantly
reduced compared with low-risk respondents (79.6, p < 0.001).
Mean index utility scores for T2D and high-risk groups (0.78
and 0.79, respectively) were substantially lower than those for
low-risk group (0.87, p < 0.001). Additionally, the mean VAS
and utility scores for T2D respondents were signiﬁcantly lower
than those of high-risk respondents (p < 0.001). Greater decre-
ments were reported in all domains by T2D and high-risk
respondents compared with low-risk respondents, with the
largest difference in decreased mobility (47.9%, 43.4%, 17.1%,
respectively). CONCLUSION: SHIELD results demonstrated
that respondents with or at higher risk for T2D report decreased
overall HRQoL, resulting from lower scores in every domain,
compared with those at low risk. Even before T2D diagnosis,
reducing cardiometabolic risk levels may lead to signiﬁcant
improvement in HRQoL.
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OBJECTIVES: The 25-Item National Eye Institute Visual Func-
tion Questionnaire (VFQ-25) was designed to assess the inﬂu-
ence of visual impairment on health-related quality of life
(HRQL). The instrument has been developed and validated in
samples of patients with various vision problems, but it has not
previously been validated speciﬁcally for use in patients with dia-
betic retinopathy (DR). The purpose of this study was to assess
the reliability and validity of the VFQ-25 in patients with DR.
METHODS: Data were from a multicenter study on vision loss
in patients with type 1 or type 2 diabetes and moderate to severe
nonproliferative DR. Visual acuity was deﬁned at each time point
as each individual’s best corrected vision as determined by the
ETDRS visual acuity chart score. Patients completed the VFQ-
